TRPS1 is a useful marker in differentiating metastatic breast carcinoma from pancreatic adenocarcinoma in fine-needle aspiration specimens
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae155 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Bahadir Yildiz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, US. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Biomarkers, Tumor, Breast Neoplasms, DNA-Binding Proteins. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Objectives
Distinction of metastatic breast carcinoma (BC) to the pancreas from primary pancreatic adenocarcinoma (PAC) is essential but challenging. Breast carcinoma shares similar morphology and exhibits an overlapping immunohistochemistry (IHC) profile with PAC. We investigated the utility of recently reported trichorhinophalangeal syndrome type 1 (TRPS1) IHC in differentiating metastatic BC from PAC in fine-needle aspiration (FNA) specimens.
Methods
We assessed consecutive patients of PAC (n = 49). Due to limited cases of metastatic BC to the pancreas (n = 3), cases of metastatic BC (n = 23) in various locations, including lymph node, lung, bone, or soft tissue, were included. Immunohistochemistry for TRPS1 was performed by using the cell blocks obtained from FNA. A quantitative score for TRPS1 expression was calculated by multiplying the intensity and the percentage of positive cells. Immunoreactivity scores were assigned as negative, low positive, intermediate positive, or high positive.
Results
In 49 PAC cases, 47 (95.9%) exhibited negative while 2 (4.1%) exhibited low positive TRPS1 expression. However, TRPS1 expression was high positive in 23 (88.0%) of 26 metastatic BC cases, including 10 (83.3%) of 12 triple-negative BC (TNBC) and 13 (92.9%) of 14 non-TNBC cases.
Conclusions
Our results suggest that TRPS1 IHC represents a highly accurate and reliable method for differentiating metastatic BC from PAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, US.
ORCID-Profile: Hiroshi Miyamoto
Zitieren
APA
Yildiz, B., Jean-Gilles, J., Giampoli, E. J., Kovar-Peltz, S., Yang, Q., Miyamoto, H., & Wang, Y. (2025). TRPS1 is a useful marker in differentiating metastatic breast carcinoma from pancreatic adenocarcinoma in fine-needle aspiration specimens. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae155
Vancouver
Yildiz B, Jean-Gilles J, Giampoli EJ, Kovar-Peltz S, Yang Q, Miyamoto H, et al. TRPS1 is a useful marker in differentiating metastatic breast carcinoma from pancreatic adenocarcinoma in fine-needle aspiration specimens. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae155
BibTeX
@article{Yildiz2025,
author = {Yildiz, Bahadir and Jean-Gilles, Jerome and Giampoli, Ellen J and Kovar-Peltz, Sierra and Yang, Qi and Miyamoto, Hiroshi and Wang, Ying},
title = {TRPS1 is a useful marker in differentiating metastatic breast carcinoma from pancreatic adenocarcinoma in fine-needle aspiration specimens},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae155}
}
EUVIMED